文献速递浆细胞疾病

骨髓瘤精准医学的未来:整合已知耐药机制与新兴肿瘤分析技术

The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies.
PubMed 文献 · Leukemia · 2019-01-25

本文综述多发性骨髓瘤(MM)已知的耐药机制及潜在可量化生物标志物,并介绍基因组、转录组和蛋白质组水平的新兴肿瘤分析技术,认为亟需在MM管理中发展和应用精准医学策略,同时需要临床试验设计与疾病管理的范式转变。

要点

  • MM仍大多不可治愈,主要因标准治疗无法克服难治性疾病和不可避免的耐药复发。
  • 近二十年临床前研究揭示恶性浆细胞逃逸标准治疗的多种机制,许多具潜在可量化生物标志物。
  • 亟需利用新兴肿瘤分析技术识别预测个体亚克隆异质性肿瘤疗效或耐药的生物标志物。

核心结论

  • 越来越明确的是,MM管理中亟需发展和应用精准医学策略,利用新兴肿瘤分析技术识别预测个体亚克隆异质性肿瘤内疗效或耐药的生物标志物。
  • 最后,我们评论了MM精准医学策略的未来实施,以及临床试验设计和疾病管理明确需要范式转变。

研究设计与样本

  • 本文为综述,更新概述了广谱类治疗耐药机制并描述了选定的潜在生物标志物示例,还概述了几种新兴肿瘤分析技术。

主要发现

  • 后基因组时代已将现代测序方法应用于大型MM患者队列,以更新对骨髓瘤病理生物学的认识并确立对MM患者间及患者内巨大异质性的理解。
  • 近二十年大量临床前研究揭示了恶性浆细胞逃逸标准治疗的机制汇编,其中许多具有潜在可量化的生物标志物。
  • 详尽的临床前努力评估了无数推定的抗MM治疗药物,其中许多已开始进入临床试验评估。
  • 虽然可用抗MM治疗的选择持续扩大,但恶性浆细胞仍具有逃逸即使最有前景的新疗法的机制途径。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is a hematologic malignancy that is considered mostly incurable in large part due to the inability of standard of care therapies to overcome refractory disease and inevitable drug-resistant relapse. The post-genomic era has been a productive period of discovery where modern sequencing methods have been applied to large MM patient cohorts to modernize our current perception of myeloma pathobiology and establish an appreciation for the vast heterogeneity that exists between and within MM patients. Numerous pre-clinical studies conducted in the last two decades have unveiled a compendium of mechanisms by which malignant plasma cells can escape standard therapies, many of which have potentially quantifiable biomarkers. Exhaustive pre-clinical efforts have evaluated countless putative anti-MM therapeutic agents and many of these have begun to enter clinical trial evaluation. While the palette of available anti-MM therapies is continuing to expand it is also clear that malignant plasma cells still have mechanistic avenues by which they can evade even the most promising new therapies. It is therefore becoming increasingly clear that there is an outstanding need to develop and employ precision medicine strategies in MM management that harness emerging tumor profiling technologies to identify biomarkers that predict efficacy or resistance within an individual's sub-clonally heterogeneous tumor. In this review we present an updated overview of broad classes of therapeutic resistance mechanisms and describe selected examples of putative biomarkers. We also outline several emerging tumor profiling technologies that have the potential to accurately quantify biomarkers for therapeutic sensitivity and resistance at genomic, transcriptomic and proteomic levels. Finally, we comment on the future of implementation for precision medicine strategies in MM and the clear need for a paradigm shift in clinical trial design and disease management.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Harding T, Baughn L, Kumar S, et al. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. Leukemia. 2019. PMID: 30683909. doi:10.1038/s41375-018-0362-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。